CatalystMarker
Sign in
← board

LLY

Eli Lilly and Companydistress 3/10 · well-funded / low risk
$1162.140%today-6% from 52w high
lilly.com50,000 employeesFounded 1876Indianapolis, INDrug Manufacturers - General
Metabolic / Obesity 1Neurology 1
Lead: Obesity · est. market ~$15B (approx, global)
Revenue
$19799M
Liquidity
$8520M
Runway
—
Shares 1y
0%

Price & events

+7.2% over 6M
$850$1043$1236Jan 26Apr 26Jul 268.2Mdilution: 424B2 offering (2026-05-08)dilution: FWP offering (2026-05-06)dilution: 424B2 offering (2026-05-06)rating: Citigroup: Buy (2026-07-15)rating: Bernstein: Outperform (2026-07-14)rating: Guggenheim: Buy (2026-07-13)rating: UBS: Buy (2026-07-13)rating: B of A Securities: Buy (2026-07-10)rating: RBC Capital: Outperform (2026-07-08)rating: Truist Securities: Buy (2026-07-08)rating: Morgan Stanley: Overweight (2026-07-08)
CatalystRating changeDilutionFinancingdashed = today
-0.1%
1D
-0.6%
1W
+5.0%
1M
+26.9%
3M
+9.6%
6M
+46.5%
1Y
+34.2%
2Y
+399.0%
5Y
+642.5%
All

Overview

Market Cap
$1.09T
Enterprise Value
$1.13T
Volume
233.09K
52 Week Range
$626 – $1236
Total Shares
941.74M
Float Shares
889.32M
Short %
1.05%
% Held by Insiders
0.15%
% Held by Institutions
85.25%
RVOL
0.08x
Beta
0.51

Pipeline stages · 40 programs

Orforglipron
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09
Retatrutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09
LY3537031
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09
LY4066708
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09
Macupatide, Eloralintide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09
LY3305677, LY3841136, Tirzepatide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09
[Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09
Tirzepatide, Retatrutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10
Pirtobrutinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10
Imlunestrant, Goserelin, Tamoxifen 20 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10
Show all 40 programs · 30 more ▾
LY4050784, Pembrolizumab, Cisplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10
Donanemab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11
Brenipatide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11
Abemaciclib, Temozolomide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11
LY3537982, Pembrolizumab, Cisplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11
Mirikizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12
Lebrikizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12
Dulaglutide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12
Eltrekibart, Mirikizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12
Eloralintide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-01
Baricitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-03
LY3884961
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-05
LY4337713
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-07
MORF-057
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-09
AAVAnc80-antiVEGF via Akouos Delivery Device
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-10
Sofetabart Mipitecan, Paclitaxel, Topotecan
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-11
Lepodisiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03
LY3962673, Cetuximab, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03
Remternetug
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-04
LY4064809, Ribociclib, Palbociclib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-05
Olomorasib, Pembrolizumab, Durvalumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-05
Vepugratinib, EV, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-10
LY3884963, Methylprednisolone, Optional Sirolimus
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-11-30
LY4066434, Cetuximab, Nab paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-01
LY4257496, Standard of Care Anticancer Therapies
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-04
LY4268989
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-06
LY4175408, Pembrolizumab, Carboplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-07
STX-478, Fulvestrant, Ribociclib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-07
Muvalaplin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-03
P-tau217 Test
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2033-07

Pipeline · 80 trials · 80 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2027-09
Estimated 50%
readout ~2027-10-01
Phase 1LY4066708Healthy, Cancer—recruiting
2027-09
Estimated 50%
readout ~2027-10-16
Phase 2Macupatide, EloralintideOverweight, Obesity—recruiting
2027-09
Estimated 50%
readout ~2027-11-15
Phase 3OrforglipronHypertension—active not recruiting
2027-09
Estimated 50%
readout ~2027-10-16
Phase 2LY3305677, LY3841136, TirzepatideObesity, Overweight—recruiting
2027-09
Estimated 50%
readout ~2027-11-15
Phase 3OrforglipronHypertension—active not recruiting
Show all 80 trials · 75 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2027-09
Estimated 50%
readout ~2027-10-01
Phase 1[Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC)Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer—active not recruiting
2027-09
Estimated 50%
readout ~2027-11-15
Phase 3RetatrutideObesity, Overweight, Chronic Low Back Pain (CLBP)—recruiting
2027-09
Estimated 50%
readout ~2027-10-16
Phase 2LY3537031Irritable Bowel Syndrome, Diarrhea—recruiting
2027-10
Estimated 50%
readout ~2027-12-15
Phase 3TirzepatideObesity, Weight Gain—recruiting
2027-10
Estimated 50%
readout ~2027-10-31
Phase 1LY4050784, Pembrolizumab, CisplatinMetastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor—recruiting
2027-10
Estimated 50%
readout ~2027-12-15
Phase 3Imlunestrant, Tamoxifen, AnastrozoleBreast Neoplasms—active not recruiting
2027-10
Estimated 50%
readout ~2027-12-15
Phase 3TirzepatideObesity, Overweight—active not recruiting
2027-10
Estimated 50%
readout ~2027-12-15
Phase 3Pirtobrutinib, IbrutinibChronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma—recruiting
2027-11
Estimated 50%
readout ~2027-12-16
Phase 2Abemaciclib, TemozolomideGlioma—active not recruiting
2027-11
Estimated 50%
readout ~2027-12-16
Phase 2BrenipatideBipolar Disorder—recruiting
2027-11
Estimated 50%
readout ~2027-12-16
Phase 2BrenipatideSchizophrenia—recruiting
2027-11
Estimated 50%
readout ~2028-01-15
Phase 3DonanemabAlzheimer Disease—active not recruiting
2027-11
Estimated 50%
readout ~2028-01-15
Phase 3LY3537982, Pembrolizumab, CisplatinCarcinoma, Non-Small-Cell Lung, Neoplasm Metastasis—recruiting
2027-12
Estimated 50%
readout ~2028-02-14
Phase 3OrforglipronObesity, Overweight—recruiting
2027-12
Estimated 50%
readout ~2028-02-14
Phase 3LebrikizumabAtopic Dermatitis, Eczema—enrolling by invitation
2027-12
Estimated 50%
readout ~2028-02-14
Phase 3DulaglutideType 2 Diabetes—recruiting
2027-12
Estimated 50%
readout ~2028-02-14
Phase 3MirikizumabCrohn's Disease—recruiting
2027-12
Estimated 50%
readout ~2028-01-15
Phase 2Eltrekibart, MirikizumabUlcerative Colitis, Ulcerative Colitis Chronic—recruiting
2028-01
Estimated 50%
readout ~2028-03-16
Phase 3EloralintideOverweight, Obesity—recruiting
2028-02
Estimated 50%
readout ~2028-04-16
Phase 3BrenipatideDepressive Disorder, Major—recruiting
2028-03
Estimated 50%
readout ~2028-05-15
Phase 3BaricitinibAreata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical—recruiting
2028-03
Estimated 50%
readout ~2028-05-15
Phase 3EloralintideOsteoarthritis, Overweight or Obesity—recruiting
2028-03
Estimated 50%
readout ~2028-04-15
Phase 2Brenipatide, BuprenorphineOpioid Use Disorder—recruiting
2028-03
Estimated 50%
readout ~2028-05-15
Phase 3EloralintideObesity, Overweight—recruiting
2028-03
Estimated 50%
readout ~2028-05-15
Phase 3OrforglipronUrinary Incontinence,Stress—recruiting
2028-03
Estimated 50%
readout ~2028-05-15
Phase 3EloralintideSleep Apnea, Obstructive, Obesity, Overweight—recruiting
2028-04
Estimated 50%
readout ~2028-05-16
Phase 2BrenipatideAsthma—recruiting
2028-04
Estimated 50%
readout ~2028-06-15
Phase 3RetatrutideObesity—active not recruiting
2028-04
Estimated 50%
readout ~2028-06-15
Phase 3Mirikizumab, TirzepatideUlcerative Colitis, Obesity or Overweight—recruiting
2028-04
Estimated 50%
readout ~2028-06-15
Phase 3LY3537031Alcohol Use Disorder—recruiting
2028-04
Estimated 50%
readout ~2028-06-15
Phase 3OrforglipronOsteoarthritis—recruiting
2028-04
Estimated 50%
readout ~2028-06-15
Phase 3LY3537031Alcohol Use Disorder—recruiting
2028-05
Estimated 50%
readout ~2028-07-15
Phase 3Mirikizumab, TirzepatideCrohn's Disease, Obesity or Overweight—recruiting
2028-05
Estimated 50%
readout ~2028-06-15
Phase 1/2LY3884961, Methylprednisolone, SirolimusGaucher Disease, Type 2—active not recruiting
2028-05
Estimated 50%
readout ~2028-07-15
Phase 3DonanemabAlzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders—active not recruiting
2028-05
Estimated 50%
readout ~2028-06-15
Phase 1/2PirtobrutinibImmune Thrombocytopenia (ITP)—recruiting
2028-06
Estimated 50%
readout ~2028-08-15
Phase 3EloralintideOverweight, Obesity—recruiting
2028-06
Estimated 50%
readout ~2028-08-15
Phase 3OrforglipronPeripheral Arterial Disease—recruiting
2028-06
Estimated 50%
readout ~2028-07-16
Phase 2PirtobrutinibChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma—recruiting
2028-07
Estimated 50%
readout ~2028-07-31
Phase 1LY4337713Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma—recruiting
2028-07
Estimated 50%
readout ~2028-09-14
Phase 3BaricitinibDiabetes Mellitus, Type 1—recruiting
2028-08
Estimated 50%
readout ~2028-09-15
Phase 2DonanemabCognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid—recruiting
2028-09
Estimated 50%
readout ~2028-10-16
Phase 2MORF-057Inflammatory Bowel Diseases, Crohn's Disease—recruiting
2028-10
Estimated 50%
readout ~2028-11-15
Phase 1/2AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and PSensorineural Hearing Loss, Bilateral—recruiting
2028-10
Estimated 50%
readout ~2028-12-15
Phase 3RetatrutideObesity, Overweight—active not recruiting
2028-11
Estimated 50%
readout ~2029-01-15
Phase 3Sofetabart Mipitecan, Paclitaxel, TopotecanOvarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis—recruiting
2029-01
Estimated 50%
readout ~2029-02-15
Phase 2Imlunestrant, Goserelin, Tamoxifen 20 mgBreast Neoplasms—recruiting
2029-02
Estimated 50%
readout ~2029-04-17
Phase 3RetatrutideAtherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)—active not recruiting
2029-03
Estimated 50%
readout ~2029-03-31
Phase 1LY3962673, Cetuximab, GemcitabinePancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer—recruiting
2029-03
Estimated 50%
readout ~2029-05-15
Phase 3Lepodisiran SodiumAtherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)—active not recruiting
2029-04
Estimated 50%
readout ~2029-06-15
Phase 3LepodisiranAtherosclerosis, Cardiovascular Diseases, Lipoprotein(a)—recruiting
2029-04
Estimated 50%
readout ~2029-06-15
Phase 3RemternetugAlzheimer's Disease—active not recruiting
2029-05
Estimated 50%
readout ~2029-07-15
Phase 3LY4064809, Ribociclib, PalbociclibBreast Neoplasms, Neoplasm Metastasis—recruiting
2029-05
Estimated 50%
readout ~2029-07-15
Phase 3Olomorasib, Pembrolizumab, DurvalumabCarcinoma, Non-Small-Cell Lung—recruiting
2029-08
Estimated 50%
readout ~2029-09-15
Phase 1/2AAVAnc80-antiVEGF via Akouos Delivery DeviceVestibular Schwannoma—recruiting
2029-09
Estimated 50%
readout ~2029-11-15
Phase 3DonanemabAlzheimer Disease, Dementia, Plaque, Amyloid—recruiting
2029-10
Estimated 50%
readout ~2029-12-15
Phase 3Vepugratinib, EV, PembrolizumabCarcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis—recruiting
2029-11-30
Estimated 50%
readout ~2030-01-14
Phase 1/2LY3884963, Methylprednisolone, Optional SirolimusFrontotemporal Dementia—active not recruiting
2030-01
Estimated 50%
readout ~2030-01-31
Phase 1LY4066434, Cetuximab, Nab paclitaxelPancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor—active not recruiting
2030-03
Estimated 50%
readout ~2030-05-15
Phase 3Orforglipron, DulaglutideDiabetes Mellitus, Type 2—not yet recruiting
2030-04
Estimated 50%
readout ~2030-06-15
Phase 3DonanemabAlzheimer Disease—recruiting
2030-04
Estimated 50%
readout ~2030-05-01
Phase 1LY4257496, Standard of Care Anticancer TherapiesBreast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms—recruiting
2030-05
Estimated 50%
readout ~2030-06-15
Phase 2PirtobrutinibLymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma—active not recruiting
2030-06
Estimated 50%
readout ~2030-07-16
Phase 2LY4268989Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe—recruiting
2030-07
Estimated 50%
readout ~2030-07-31
Phase 1LY4175408, Pembrolizumab, CarboplatinCarcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer—recruiting
2030-07
Estimated 50%
readout ~2030-08-15
Phase 1/2STX-478, Fulvestrant, RibociclibBreast Cancer, Solid Tumors, Adult—recruiting
2030-08
Estimated 50%
readout ~2030-10-15
Phase 3Tirzepatide, RetatrutideMetabolic Dysfunction-Associated Steatotic Liver Disease—recruiting
2030-12
Estimated 50%
readout ~2031-02-14
Phase 3MirikizumabUlcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease—recruiting
2030-12-31
Estimated 50%
readout ~2031-02-14
Phase 1/2LY3884961, Methylprednisolone, SirolimusParkinson Disease—active not recruiting
2031-03
Estimated 50%
readout ~2031-05-15
Phase 3MuvalaplinElevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)—recruiting
2031-07
Estimated 50%
readout ~2031-09-14
Phase 3BaricitinibJuvenile Idiopathic Arthritis—recruiting
2031-07
Estimated 50%
readout ~2031-09-14
Phase 3BaricitinibDiabetes Mellitus, Type 1—recruiting
2031-08
Estimated 50%
readout ~2031-10-15
Phase 3OrforglipronAtherosclerosis Cardiovascular Disease, Chronic Kidney Disease—recruiting
2032-08-30
Estimated 50%
readout ~2032-10-14
Phase 1/2LY3884961Gaucher Disease, Gaucher Disease, Type 1—recruiting
2033-07
Estimated 50%
readout ~2033-09-14
Phase 3P-tau217 TestAlzheimer Disease—recruiting

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (4)

  • KISUNLADONANEMAB-AZBT2024 · Prescription
  • REZVOGLARINSULIN GLARGINE-AGLR2022 · Prescription
  • PORTRAZZANECITUMUMAB2015 · Prescription
  • ADCIRCATADALAFIL2009 · Prescription

Capital structure — dilution & financing

Shares out: 941,741,406 · 6 offerings/1y · 0 PIPEs
  • 2026-05-08424B2offering
  • 2026-05-06424B2offering
  • 2026-05-06FWPoffering
  • 2025-08-19424B2offering
  • 2025-08-18424B2offering
  • 2025-08-18FWPoffering
  • 2025-02-19S-3ASRshelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $1270 (+9% upside) · 27 analysts
  • 2026-07-15CitigroupBuy
  • 2026-07-14BernsteinOutperform
  • 2026-07-13GuggenheimBuy
  • 2026-07-13UBSBuy
  • 2026-07-10B of A SecuritiesBuy
  • 2026-07-08RBC CapitalOutperform

Competitors — Obesity

  • AMGNAMGEN INC$195.4B · D3
  • GPCRStructure Therapeutics Inc.$11.2B · D4
  • RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
  • MBXMBX Biosciences, Inc.$2.8B · D2
  • WVEWave Life Sciences Ltd.$1.1B · D1
  • CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
  • GUTSFRACTYL HEALTH, INC.$123M · D9
  • VANIVivani Medical, Inc.$118M · D7
  • MTVAMetaVia Inc.$8M · D7
  • NONOFNOVO NORDISK A S— · D2

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.